1258392-53-8
1258392-53-8 structure
- Name: AZD5582
- Chemical Name: (2S,2'S)-N,N'-{2,4-Hexadiyne-1,6-diylbis[oxy(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]}bis{1-[(2S)-2-cyclohexyl-2-{[(2S)-2-(methylamino)propanoyl]amino}acetyl]-2-pyrrolidinecarboxamide} (non-preferred name)
- CAS Number: 1258392-53-8
- Molecular Formula: C58H78N8O8
- Molecular Weight: 1015.289
- Catalog: Signaling Pathways Apoptosis IAP
- Create Date: 2018-02-21 14:39:32
- Modify Date: 2024-01-03 16:03:16
-
AZD5582 is a novel class of dimeric Smac mimetics as potent IAP antagonist; binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively). IC50 value: 15/21/15 nM (cIAP1/cIAP2/XIAP) [1]Target: IAPs inhibitorAZD5582 causes cIAP1 degradation and induces apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concentrations in vitro. When administered intravenously to MDA-MB-231 xenograft-bearing mice, AZD5582 results in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg. Antiproliferative effects are observed with AZD5582 in only a small subset of the over 200 cancer cell lines examined, consistent with other published IAP inhibitors [1]. AZD5582 significantly enhanced apoptosis induced by the death receptor (DR) agonist tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Importantly, killing by TRAIL plus AZD5582 was independent of adverse prognostic features including TP53 deletion which is strongly associated with chemoresistance in CLL [2].
| Name | (2S,2'S)-N,N'-{2,4-Hexadiyne-1,6-diylbis[oxy(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]}bis{1-[(2S)-2-cyclohexyl-2-{[(2S)-2-(methylamino)propanoyl]amino}acetyl]-2-pyrrolidinecarboxamide} (non-preferred name) |
|---|---|
| Synonyms |
(2S,2'S)-N,N'-{2,4-Hexadiyne-1,6-diylbis[oxy(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]}bis{1-[(2S)-2-cyclohexyl-2-{[(2S)-2-(methylamino)propanoyl]amino}acetyl]-2-pyrrolidinecarboxamide} (non-preferred name)
2-Pyrrolidinecarboxamide, N,N'-[2,4-hexadiyne-1,6-diylbis[oxy[(1S,2R)-2,3-dihydro-1H-indene-2,1-diyl]]]bis[1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)-1-oxopropyl]amino]acetyl]-, (2S,2'S)- AZD5582 |
| Description | AZD5582 is a novel class of dimeric Smac mimetics as potent IAP antagonist; binds potently to the BIR3 domains of cIAP1, cIAP2, and XIAP (IC50 = 15, 21, and 15 nM, respectively). IC50 value: 15/21/15 nM (cIAP1/cIAP2/XIAP) [1]Target: IAPs inhibitorAZD5582 causes cIAP1 degradation and induces apoptosis in the MDA-MB-231 breast cancer cell line at subnanomolar concentrations in vitro. When administered intravenously to MDA-MB-231 xenograft-bearing mice, AZD5582 results in cIAP1 degradation and caspase-3 cleavage within tumor cells and causes substantial tumor regressions following two weekly doses of 3.0 mg/kg. Antiproliferative effects are observed with AZD5582 in only a small subset of the over 200 cancer cell lines examined, consistent with other published IAP inhibitors [1]. AZD5582 significantly enhanced apoptosis induced by the death receptor (DR) agonist tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Importantly, killing by TRAIL plus AZD5582 was independent of adverse prognostic features including TP53 deletion which is strongly associated with chemoresistance in CLL [2]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 1207.3±65.0 °C at 760 mmHg |
| Molecular Formula | C58H78N8O8 |
| Molecular Weight | 1015.289 |
| Flash Point | 683.9±34.3 °C |
| Exact Mass | 1014.594238 |
| LogP | 9.22 |
| Vapour Pressure | 0.0±0.3 mmHg at 25°C |
| Index of Refraction | 1.622 |
| Storage condition | 2-8℃ |